Background-Alterations in cardiac energy metabolism downstream of neurohormonal stimulation play a crucial role in the pathogenesis of heart failure. The chronic adrenergic stimulation that accompanies heart failure is a signaling abnormality that leads to the upregulation of G protein-coupled receptor kinase 2 (GRK2), which is pathological in the myocyte during disease progression in part owing to uncoupling of the ␤-adrenergic receptor system. In this study, we explored the possibility that enhanced GRK2 expression and activity, as seen during heart failure, can negatively affect cardiac metabolism as part of its pathogenic profile. Methods and Results-Positron emission tomography studies revealed in transgenic mice that cardiac-specific overexpression of GRK2 negatively affected cardiac metabolism by inhibiting glucose uptake and desensitization of insulin signaling, which increases after ischemic injury and precedes heart failure development. Mechanistically, GRK2 interacts with and directly phosphorylates insulin receptor substrate-1 in cardiomyocytes, causing insulin-dependent negative signaling feedback, including inhibition of membrane translocation of the glucose transporter GLUT4. This identifies insulin receptor substrate-1 as a novel nonreceptor target for GRK2 and represents a new pathological mechanism for this kinase in the failing heart. Importantly, inhibition of GRK2 activity prevents postischemic defects in myocardial insulin signaling and improves cardiac metabolism via normalized glucose uptake, which appears to participate in GRK2-targeted prevention of heart failure. Conclusions-Our data provide novel insights into how GRK2 is pathological in the injured heart. Moreover, it appears to be a critical mechanistic link within neurohormonal crosstalk governing cardiac contractile signaling/function through ␤-adrenergic receptors and metabolism through the insulin receptor. (Circulation. 2011;123:1953-1962.) (G.I.). The online-only Data Supplement is available with this article at http://circ.ahajournals.org/cgi/content/full/CIRCULATIONAHA.110.988642/DC1.
D espite improvements in the treatment of heart failure (HF), the prognosis of this disease remains poor. 1, 2 The reason that HF continues to worsen even in patients receiving optimal therapy is unclear; however, there is increasing evidence that perturbations in cardiac metabolism can contribute to the progression of cardiomyopathy and to a loss of pharmacological effectiveness. 3, 4 Therefore, approaches targeting more efficient substrate use and preservation of cardiac metabolism are attractive therapeutic strategies. 5 In the adult heart, the major pathway for ATP production is fatty acid oxidation, 6, 7 whereas the relative contribution of glucose increases during stress or injury such as during exercise or ischemia. 5 During HF, there are excessive uptake and myocardial free fatty acid accumulation with reduced glucose use. 8, 9 In animal models of HF and in human disease, these metabolic alterations reduce myocardial oxygen efficiency and lead to a depletion of intracellular ATP. 10, 11 
Clinical Perspective on p 1962
Insulin receptor signaling is critically involved in increasing glucose uptake in the myocardium, and cardiac insulin resistance contributes to the development of left ventricular (LV) dysfunction by reducing cardiac efficiency through metabolic shift toward fatty acids use. 12 Indeed, a profound state of insulin resistance has been found in the hearts of ob/ob mice, and the ability of these hearts to modulate substrate use in response to insulin and changes in fatty acid supply is altered. 13 Importantly, normalization of cardiac metabolism by overexpressing a human GLUT4 transgene in mice with insulin resistance recovered the altered cardiac function observed in these animals. 14, 15 Therefore, these studies indicate that cardiac insulin resistance reduces the metabolic efficiency of the heart, which can lead to contractile dysfunction. Moreover, insulin resistance is a known and recognized phenomenon leading to HF, 16 as seen in positron emission tomographic (PET) studies showing that failing human myocardium has reduced glucose uptake and increased free fatty acid uptake. 17 Several hypotheses have been proposed to explain the association between altered cardiac metabolism, insulin resistance, and HF. Among these hypotheses, there is a strong correlation with neurohormonal activation, 18, 19 which increases plasma free fatty acid levels and inhibits insulin receptor signaling, resulting in a loss of myocyte glucose uptake. 20 An important abnormality in the myocyte induced by neurohormonal activation in HF is the upregulation of G protein-coupled receptor kinase 2 (GRK2), which classically phosphorylates activated G protein-coupled receptors such as the ␤-adrenergic receptors (␤ARs) in the heart, leading to attenuated signaling. 21 In human HF, increased GRK2 is associated with lower cardiac function and prognosis. 22, 23 Recent evidence suggests that GRK2 can have non-G protein-coupled receptor effects, including playing an unidentified role in the regulation of insulin signaling in noncardiac cells. 24, 25 Moreover, increases in GRK2 activity after ␤AR stimulation inhibit insulin-dependent glucose extraction. 26 Therefore, we hypothesized that increased levels of GRK2, as seen during HF, directly induce myocardial insulin resistance, and given the importance of cardiac signaling for efficient metabolic substrate use, we have studied the role of GRK2 in regulating cardiac insulin signaling and metabolism in normal and postischemic myocytes and hearts. Our data reveal a role for GRK2 in HF pathogenesis that extends beyond the known negative effects on ␤AR signaling and cardiac contractility by demonstrating that GRK2 can critically and negatively affect cardiac insulin signaling and metabolism.
Methods

Experimental Procedures
Experimental procedures were performed essentially as described previously. 27, 28 An expanded Methods section appears in the onlineonly Data Supplement.
Statistical Analyses
All experiments were performed at least in triplicate using cell isolates from different rats. The results were expressed as meanϮSEM. We used Prism 4 and SPSS 17 to perform statistical analysis with a 2-tailed Student t test for in vitro studies and 2-way and repeated measures ANOVA with a Bonferroni posthoc test for the in vivo studies. SPSS was used to evaluate the normal distribution according to the Levene test for normality and to provide different P values for unpaired samples, depending on normal distribution. Even when the data are not normally distributed, we still found significant differences between means of different treatments and/or groups. A value of PϽ0.05 was considered statistically significant.
Results
G Protein-Coupled Receptor Kinase 2 Levels Influence In Vivo Cardiac Glucose Uptake
We first examined whether increased GRK2 in cardiomyocytes can alter in vivo glucose uptake in the hearts of mice after insulin treatment. This is important because myocardial GRK2 upregulation occurs immediately after ischemic injury 29 and may trigger further signaling defects. Therefore, we performed micro-PET using 18-fluorodeoxyglucose in transgenic mice with cardiac-specific GRK2 overexpression (Tg-GRK2 30 ) and their nontransgenic littermate controls (NLCs). An insulin injection produces a robust increase in in vivo 18-FDG accumulation in the hearts of NLC mice, which is significantly lower in Tg-GRK2 mice ( Figure 1A ). Mechanistically, GRK2 enhancement appears to cause a loss of insulin-dependent GLUT4 membrane translocation ( Figure 1B ).
G Protein-Coupled Receptor Kinase 2 Regulation of Insulin Signaling in Cardiomyocytes
Because of the above provocative in vivo results, we explored molecular mechanisms involving GRK2 and insulin signaling in cultured adult rat ventricular cardiomyocytes (ARVMs). As expected, when ARVMs were exposed to insulin, GLUT4 membrane translocation was induced, as was the activation of the downstream kinase, Akt (Figure 2A through 2C). Unexpectedly, we found that insulin induced the membrane translocation of GRK2 (Figure 2A and 2D). The cause of GRK2 membrane translocation after insulin administration is unclear, but we next evaluated whether increased membrane GRK2 levels could alter downstream insulin receptor signaling. To do this, we prestimulated ARVMs with the ␤AR agonist isoproterenol to cause G␤␥-dependent GRK2 translocation, which was evident in ARVMs ( Figure  2A and 2). Interestingly, after isoproterenol pretreatment, insulin failed to induce GLUT4 translocation, and there was significantly less insulin-dependent Akt activation (Figure 2A through 2C).
To further explore how GRK2 levels may alter myocyte insulin signaling, we overexpressed GRK2 in ARVMs using an adenovirus (AD; ADGRK2). We found that increased GRK2 in ARVMs attenuated insulin-stimulated Akt activation and GLUT4 membrane translocation compared with control myocytes infected with AD green fluorescent protein (GFP; Figure 3A and 3B). Reduced GLUT4 translocation is consistent with the above findings in Tg-GRK2 mice showing that enhanced GRK2 can lead to a loss of insulin-dependent in vivo cardiac glucose uptake. Indeed, we found that insulin-dependent [H 3 ]-deoxyglucose uptake in ARVMs was significantly attenuated by ADGRK2 ( Figure 3C ).
G Protein-Coupled Receptor Kinase 2 Activity Is Required for Attenuation of Cardiomyocyte Insulin Signaling via Direct Phosphorylation of Insulin Receptor Substrate-1
Mechanistically, GRK2 could exert its inhibitory effect on insulin-dependent GLUT4 translocation and cardiomyocyte glucose uptake and metabolism through different pathways. GLUT4 membrane translocation has been shown to be dependent on G␣q/11 signaling, 25 and GRK2 has a known RGS domain within its aminoterminus that can interact directly with G␣q and inhibit its activity. Furthermore, GRK2 has recently been shown to interact with and inhibit Akt in endothelial cells. 31 We conducted experiments to test these possible mechanisms and found no evidence that GRK2 interacted with either of these proteins in ARVMs, either basally or after stimulation of cells with insulin (data not shown). Therefore, we explored the possibility that GRK2 could regulate insulin signaling in cardiomyocytes in other ways. Of note, kinase activity of GRK2 was necessary for the negative regulation of insulin signaling because the kinasedead (K220R) GRK2 dominant-negative mutant (GRK2DN) failed to alter Akt activation ( Figure 4A ) and GLUT4 membrane translocation in response to insulin ( Figure 4B ).
We next focused our attention on a potential regulatory role of GRK2 on insulin receptor substrate-1 (IRS1). This molecule moves to the plasma membrane after insulin stimulation and binds activated insulin receptors, leading to Tyr phosphorylation and subsequent activation of downstream signaling. 21 The association of IRS1 with the insulin receptor also initiates events that lead to the attenuation of the Figure 1 . G protein-coupled receptor kinase 2 (GRK2) levels influence in vivo cardiac glucose uptake. A, Transgenic (Tg)-GRK2 and nontransgenic littermate control (NLC) mice were studied by positron emission tomography to evaluate cardiac glucose uptake after intraperitoneal injection of insulin (Ins; 0.075 U/kg IP). Insulin significantly increases glucose uptake; however, this response was attenuated in BK12 mice (*PϽ0.05, Ins vs basal; §PϽ0.05, Tg-GRK2 vs NLC; nϭ8 per group). SUV indicates standardized uptake values. B, Plasma membrane GLUT4 protein levels from Tg-GRK2 and NLC hearts. Animals were injected with Ins as above and euthanized 15 minutes later. The GLUT4 levels on the plasma membrane were increased by Ins in NLC but attenuated in Tg-GRK2. The GLUT4 level was normalized to the membrane protein G␤ (*PϽ0.05, Ins vs basal; §PϽ0.05, fold of increased translocation to the membrane, Tg-GRK2 vs NLC; nϭ3 per group).
Figure 2.
Interplay between ␤-adrenergic receptor (␤AR and insulin receptor signaling. Adult rat ventricular cardiomyocytes were stimulated with insulin (Ins; 0.1 mol/L for 10 minutes) with or without pretreatment with the ␤AR agonist isoproterenol (Iso; 10 mol/L for 5 minutes). Membrane fractions were prepared and blotted for signaling proteins. A, Representative Western blot showing membrane GLUT4, phosphorylated (p) Akt, and G protein-coupled receptor kinase 2 (GRK2). G␤ blotting was used as loading control. B through D, Bar graphs showing GLUT4 translocation (*PϽ0.05, Ins vs basal; nϭ3; **PϭNS, IsoϩIns vs Iso; nϭ3 per group). Akt was activated in response to Ins but attenuated with Iso pretreatment ( §PϽ0.05, fold activation, IsoϩIns vs Ins alone; nϭ3 per group) and GRK2 translocation induced by Ins with or without Iso pretreatment (* §PϽ0.05, Ins, Iso, and IsoϩIns vs basal; nϭ3 per group).
biological effects of insulin 32 through phosphorylation of IRS1 at Ser307, which disrupts IRS1 binding to the insulin receptor and promotes its proteasomal degradation. 33 Of note, when IRS1 is phosphorylated at Ser307, there is a reduction in Tyr612 phosphorylation, and there appears to be a reciprocal relationship between these 2 sites of posttranslational modification. 24, 33 A recent study has shown a physical interaction between GRK2 and IRS1 in adipocytes and muscle cells under basal conditions, which is disrupted by insulin treatment. 34 However, our experiments in adult cardiac myocytes show that both GRK2 and IRS1 translocate to the plasma membrane. Moreover, they associate together, and this interaction increases on insulin treatment of myocytes ( Figure IA and IB in the online-only Data Supplement). Therefore, we pursued the hypothesis that increased GRK2 activity might enhance the feedback loop induced by insulin via IRS1 inhibitory phosphorylation. We observed that overexpression of GRK2 itself significantly increased Ser307 phosphorylation of IRS1 under basal conditions and after insulin treatment compared with ADGFP-infected cells ( Figure 4C ).
To address this potential specific role of GRK2 in myocyte insulin signaling, we studied levels of phospho-Ser307 IRS1 in isolated cells from NLC, Tg-GRK2, and cardiac-specific GRK2 knockout (KO) mice 27 after insulin administration. Figure 4D shows that increased cardiac GRK2 in Tg-GRK2 ARVMs results in increased basal and insulin-stimulated IRS1 phospho-Ser307 levels, whereas GRK2KO myocytes have attenuated insulin-stimulated phosphorylation of IRS1 at Ser307 compared with NLC myocytes. Importantly, an in vitro kinase assay shows that purified GRK2 directly phosphorylates purified GST-IRS1 at Ser307 ( Figure 4E ). The physiological relevance of GRK2 phosphorylation of Ser307 in insulin signaling regulation was explored by using an IRS1 in which Ser307 was mutated to alanine, which could not be phosphorylated by GRK2 ( Figure IC in the online-only Data Supplement). Overexpression of this mutated IRS1 by adenovirus (ADIRS1mt) in neonatal rat ventricular cardiomyocytes removes the ADGRK2 inhibitory effects on insulinmediated activation of Akt ( Figure 4F ) and GLUT4 translocation to the membrane ( Figure ID in the online-only Data Supplement).
Consistent with GRK2 activity inducing Ser307 phosphorylation of IRS1, an inhibitory phosphorylation, we found that GRK2, but not the kinase-dead GRK2 mutant (K220R), also reduced the stimulatory-signaling Tyr612 phosphorylation in ARVMs ( Figure IE in the online-only Data Supplement). . D, Level of p-Ser307 of IRS1 was evaluated by immunoprecipitation of equal amounts of IRS1 from isolated myocytes of nontransgenic littermate controls (NLC), transgenic (Tg)-GRK2, and cardiac GRK2 knockout (KO) mice after stimulation with Ins (10 Ϫ7 mol/L; 10 minutes). Representative blots for GRK2, p-Ser307, IRS1, and total (t) IRS1 are shown. Reduced and increased levels of pSer307IRS1 were observed in GRK2KO and Tg-GRK2, respectively, vs NLC (*PϽ0.01, fold of activation, GRK2KO vs NLC; nϭ3; **PϽ0.01, Tg-GRK2 vs NLC; nϭ3 per group). E, GRK2 phosphorylates IRS1 at Ser307. An in vitro kinase assay was performed with purified GST-IRS1 alone (none) or in the presence of ATP or ATP plus purified GRK2. Representative blot from 3 independent assays (top) and densitometric analysis (bottom) are shown (*PϽ0.05, fold activation vs ATP and none). F, Neonatal rat ventricular cardiomyocytes (NRVMs) were coinfected with either ADIRS1 wild type (wt) or ADIRS1 mutant Ser307Ala (mt) in addition to ADGFP or ADGRK2 and stimulated with Ins as above. Representative immunoblot showing p-Akt levels is provided (*PϽ0.01, fold activation vs ADGRK2ϩADIRS1wt; nϭ3 per group).
Cardiac Glucose Uptake Defects Precede Heart Failure Development After Myocardial Infarction, and Both Are Augmented With G Protein-Coupled Receptor Kinase 2 Upregulation
With our findings that increased GRK2 levels in myocytes negatively affect insulin signaling, we next sought to determine whether this translates to the pathogenesis of HF. To determine whether GRK2-mediated loss of glucose metabolism occurs in compromised myocardium, we used micro-PET to follow 18-FDG uptake after myocardial infarction (MI). Left coronary artery ligation induced a reproducible LV infarct in Tg-GRK2, GRK2KO, and NLC mice, as previously described 27 (data not shown). All groups showed increased 18-FDG uptake 1 week after MI, consistent with the heart increasing to the more protective glucose metabolism. 5 However, the immediate post-MI glucose uptake response was significantly reduced in Tg-GRK2 mice compared with NLC ( Figure 5A ). Furthermore, a progressive reduction in glucose uptake after MI is observed in both NLC and Tg-GRK2 mice, which accompanies progressive post-MI cardiac dysfunction and LV remodeling as measured by echocardiography ( Figure 5B ). In cardiac GRK2KO mice, there was an initial lower glucose uptake response immediately after MI; however, in vivo glucose uptake remained stable throughout the study period, resulting in significantly higher uptake compared with the NLC group at 6 to 8 weeks after MI ( Figure 5A ). Interestingly, as in ARVMs ( Figure 3C ), attenuated cardiac glucose uptake in vivo over time was significantly attenuated with GRK2 overexpression, and this worsened metabolic effect was most evident 1 to 3 weeks after MI ( Figure 5A ). These data show that higher levels of myocardial GRK2 cause immediate post-MI defects in glucose metabolism that are evident before LV dysfunction appears; accordingly, Tg-GRK2 mice have significantly worse cardiac function and remodeling longterm after MI, whereas cardiac GRK2KO mice showed a preserved glucose use, resulting in preserved cardiac volume and function ( Figure 5B and 5C ).
Carboxyl Terminal Domain of G Protein-Coupled Receptor Kinase 2 Improves Insulin Signaling in Adult Cardiomyocytes
Our data indicate that excess GRK2 produces serious modifications in cardiac glucose uptake and insulin signaling in vivo and in vitro. Inhibition of GRK2 activity through the carboxyl terminal domain of GRK2 (␤ARKct) has previously rescued several models of HF. 21, 29 In light of the above data showing, in particular, the protective role of myocardial GRK2 loss on cardiac metabolism, we hypothesized that the beneficial effect of ␤ARKct in rescuing cardiac function during HF could be due, at least in part, to a favorable effect on cardiac metabolism. Indeed, transgenic mice with cardiac ␤ARKct expression (Tg-␤ARKct) have significantly lower inhibitory IRS1 Ser307 phosphorylation induced by insulin ( Figure 6A ), similar to data in cardiacspecific GRK2 KO mice ( Figure 4D ). Therefore, ␤ARKct has the potential to enhance insulin signaling. We tested this hypothesis by introducing ␤ARKct in ARVMs via an adenovirus (AD␤ARKct). We found that ␤ARKct expression restores and enhances Akt phosphorylation and a downstream target of Akt, GSK3␤, compared with levels found in ADGRK2-and ADGFP-treated myocytes, respectively ( Figure 6B and 6C ). 
AAV6 -Carboxyl Terminal Domain of G Protein-Coupled Receptor Kinase 2 Gene Therapy Prevents G Protein-Coupled Receptor Kinase 2-Mediated Defects in Cardiac Glucose Metabolism Before the Rescue of Subsequent Heart Failure
Next, we asked whether inhibiting GRK2 could lift the negative effects of this kinase on in vivo myocardial insulin signaling and measured myocardial glucose uptake and insulin responses in post-MI rat hearts that expressed ␤ARKct. To do this, we injected AAV6-GFP or AAV6-␤ARKct into the myocardium of rats during surgery to induce an MI, as we have done previously. 28 Then, we serially measured in vivo glucose uptake in the heart via micro-PET, along with LV dimension and function via echocardiography and LV catheterization. As expected, our method of cardiac gene transfer led to long-term and robust ␤ARKct expression in the rat heart ( Figure IIA in the online-only Data Supplement). AAV6-␤ARKct delivery compared with AAV6-GFP did not produce any significant differences in cardiac function and volume in sham-treated rats (data not shown); therefore, in our data presentation, we show only 1 sham control group.
MI induces progressive dilatation and LV dysfunction (Figure IIC and IID and Table I in the online-only Data Supplement), and consistent with human and animal models of HF, we found a progressive increase in myocardial GRK2 levels after MI ( Figure IIB in the online-only Data Supplement). Rats treated with AAV6-␤ARKct had significantly improved post-MI cardiac function and significantly less remodeling throughout the 12 weeks of study (Figure IIC and  IID and Table I in the online-only Data Supplement) with respect to the AAV6-GFP group. When we assessed in vivo Figure 6 . Inhibition of G protein-coupled receptor kinase 2 (GRK2) in myocytes and myocardium restores normal insulin (Ins) signaling and prevents defective in vivo glucose uptake after myocardial infarction (MI). A, Level of Ins-stimulated phosphorylated (p) Ser307 in insulin receptor substrate-1 (IRS1) immunoprecipitated (IP) from adult mouse ventricular myocytes isolated from nontransgenic littermate controls (NLC), transgenic (Tg)-GRK2, or Tg-carboxyl terminal domain of GRK2 (Tg-␤ARKct mice) (*PϽ0.01 vs NLC; nϭ3; §PϽ0.01, Tg-␤ARKct vs NLC; nϭ3 per group). IB indicates immunoblot. B, Adult rat ventricular myocytes (ARVMs) were infected with adenovirus (AD) green fluorescent protein (GFP), ADGRK2, or AD␤ARKct. Representative blots for p-Akt and total (t) Akt are shown (*PϽ0.01, fold increase in activation, ADGRK2 vs ADGFP; nϭ3; **PϽ0.01, fold increase in activation, AD␤ARKct vs ADGRK2 and ADGFP; nϭ3 per group). C, Representative Western blot from ARVM whole lysate infected as in A and stimulated with Ins showing p-GSK3␤ and t-GSK3␤ (*PϽ0.01, fold increase in activation, ADGRK2 vs ADGFP; nϭ3; **PϽ0.01, fold increase in activation, AD␤ARKct vs ADGRK2; nϭ3). D, Global rat myocardial in vivo glucose uptake evaluated by micro-positron emission tomography in sham and 1-, 3-, 6-, and 12-week post-MI rats treated with AAV6-GFP or AAV6-␤ARKct (*PϽ0.05 vs AAV6GFP; nϭ8 per group). E, Rats 3 weeks after MI and sham were euthanized 15 minutes after an intraperitoneal injection of insulin (0.075 U/kg), and hearts were removed. Plasma membranes were prepared to evaluate GLUT4 levels as shown in a representative blot (*PϽ0.05 vs basal; §PϽ0.05 vs basal; nϭ3 per group). glucose uptake after MI via micro-PET, we found that MI caused an immediate defect in 18-FDG uptake in control AAV6-GFP-treated rats; this metabolic abnormality was evident before any cardiac dysfunction or remodeling was found ( Figure 6D ), a finding that was similar to the above studies in mice ( Figure 5 ). Interestingly, AAV6-␤ARKct-treated rats actually had normal myocardial glucose uptake 3 weeks after MI, and this was significantly improved over post-MI GFP-treated rats throughout the study ( Figure 6D ). To evaluate the potential in vivo mechanism of the above PET results, we took a cohort of 3-week post-MI rats and challenged them with insulin to measure GLUT4 membrane localization and found this to be significantly blunted in GFP-treated rats. However, AAV6-␤ARKct-treated animals had significantly improved insulin responsiveness ( Figure 6E ).
Discussion
Our findings add significantly to the dynamic role of GRK2 in the pathogenesis of HF in that they uncover a new mechanism by which upregulated GRK2 in the injured myocardium promotes ventricular dysfunction. Importantly, enhanced GRK2 activity not only negatively affects cardiac contractile function after myocardial injury, but also causes abnormal cardiac metabolism. Furthermore, GRK2 may represent a molecular link between the excessive neurohormonal activation that follows cardiac stress and initiation of defects in myocyte energy substrate use. Of note, our data reveal that GRK2 inhibition via ␤ARKct expression or its gene deletion in myocytes corrects metabolic alterations observed during the early stages of postischemic HF. This facilitates myocyte use of glucose, which is a protective metabolic substrate, and delays the development of HF.
As observed in our micro-PET studies, the modification in cardiac glucose uptake is an early event after the induction of MI. In particular, the initial increase is followed by a progressive reduction, which is then accompanied by a progressive cardiac dilation and reduced function. This behavior observed in NLC mice is significantly modified in mice with altered GRK2 levels in myocytes. Enhanced GRK2 cardiac expression in Tg-GRK2 mice significantly reduces protective myocyte glucose uptake, whereas cardiac-targeted GRK2KO mice have preserved glucose uptake throughout the 8-week post-MI period. Given the higher efficiency of glucose in ATP production and the lower impact in oxidative stress with respect to other substrates, we show that GRK2mediated pathogenesis in HF is mediated, at least in part, through negative alterations in cardiac metabolism.
Our findings once again highlight the deleterious effects of increased GRK2 levels that accompany myocardial ischemia, and, most important, confirm the importance of identifying strategies aimed specifically to reduce its activity in the heart as potential HF therapy. Moreover, GRK2 inhibition with ␤ARKct, which has been demonstrated to rescue or prevent animal models of HF and to improve contractile function of failing human ventricular myocytes, 28, 35 has beneficial effects that extend beyond the functional recovery of ␤ARs and contractility. Indeed, previous studies showed that GLUT4 overexpression improves cardiac function in mice with cardiac insulin resistance. 14, 15 We demonstrate here that lower-ing GRK2 during HF improves glucose uptake and delays the development of the disease. We attribute at least part of the improvement to restored insulin-stimulated GLUT4 membrane translocation. G protein-coupled receptor kinase 2 also represents the first identification of a molecule that represents a nodal link between excessive neurohormonal stimulation and metabolic abnormalities, supporting the hypothesis that strategies aimed to preserve myocardial metabolism could be beneficial in the treatment or prevention of HF.
Insulin signaling is known to be protective in the heart by inhibiting apoptosis and oxidative stress 36 ; it is also an important regulator of cardiac mass. 37 These effects are mediated primarily by activation of PI3K-Akt and inhibition of GSK3␤. 38 On the basis of the results of this study, injury-induced increases in GRK2 within the cardiomyocyte may increase oxidative stress, which expands our mechanistic understanding of why Tg-GRK2 mice progress more rapidly to HF. Therefore, GRK2 clearly has effects in the myocyte that extend beyond G protein-coupled receptor-mediated functions, improving our mechanistic understanding of the pathological nature of GRK2 in the heart.
Of interest, recent studies have described a correlation between insulin resistance and increased levels of GRK2 in pathological conditions. In particular, Garcia-Guerra et al 34 have recently found that overexpression of either GRK2 or the kinase-dead mutant reduces insulin sensitivity in myoblasts and adipocytes, and that finding was consistent with other studies 25, 31 that suggested that a kinase-independent mechanism was involved, possibly by sequestering molecules involved in insulin signaling such as G␣q/11, Akt, and IRS1. However, our data demonstrate for the first time that the catalytic activity of GRK2 is fundamental and a requirement in postischemic cardiac metabolic alterations, in particular, the dampening insulin signaling.
The finding that Ser307 of IRS1 is a target for GRK2 phosphorylation in cardiomyocytes significantly increases the overall knowledge about the regulation of insulin signaling in physiology and pathology. Several serine residues within IRS1 are involved in the physiological mechanism of IRS1 inhibition; however, Ser307 has specific properties and characteristics that make it particularly interesting as a target of GRK2. This site is found proximal to the IRS1 phospho-Tyr binding domain, and Ser307 phosphorylation rapidly reduces its affinity for binding to the insulin receptor, 33 a process that resembles ␤AR desensitization. Thus, GRK2 appears to directly modulate signaling through this non-G proteincoupled receptor and participates in the physiological regulation of insulin signaling. Accordingly, GRK2 inhibition reduces insulin-mediated Ser307 phosphorylation and improves signaling, and as a result can improve glucose uptake and insulin resistance in the injured cardiomyocyte. Indeed, elevated levels of phospho-Ser307 of IRS1 have been observed in animal models of insulin resistance, and the equivalent Ser312 site in human IRS1 has been demonstrated to be hyperphosphorylated in insulin-resistant subjects. 39, 40 Therefore, our findings can hypothetically be extended beyond the heart, and suggest that ␤ARKct gene therapy could be used for the possible treatment of reduced skeletal muscle and liver glucose uptake, as is observed in type II diabetes mellitus.
Overall, our data show that GRK2 inhibition clearly delays the reduction in glucose uptake and protects insulin signaling in the heart, preserving cardiac dimension and function. These data support the novel hypothesis that part of the therapeutic effect of GRK2 inhibition in HF includes correction of abnormal cardiac metabolism.
